Living Donor Kidney TransplantationMuST AKTNCT04666545
Multidisciplinary Support To Access Living Donor Kidney Transplant-Pilot
A study testing MuST AKT in people with Living Donor Kidney Transplantation, run by University of Alberta at 1 site in Canada.
Trial summary
For patients with kidney failure the two treatment options are kidney transplantation or dialysis. Transplantation offers longer survival, better quality of life and provides cost savings for the health system (>$60,000/year per patient). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Living Donor Kidney Transplantation
- What is being tested?
- MuST AKT
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteCanada
- Study dates
- 12 May 2021to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- English speaking
- No obvious contraindication to kidney transplantation
- Completed 'introduction to kidney transplant' module
Who cannot join
- Potential Living Kidney Donor identified
- Previously received organ transplant
- Candidate for multi-organ transplant
- Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) Score > 20
- Rapid Estimate of Adult Literacy in Medicine (REALM-66) score < 19 (illiterate in English)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Multidisciplinary Support To Access Living Donor Kidney Transplant (MuST AKT)- A Pilot Randomized Controlled Trial
For patients with kidney failure the two treatment options are kidney transplantation or dialysis. Transplantation offers longer survival, better quality of life and provides cost savings for the health system (>$60,000/year per patient). Unfortunately, there are not enough organs available and 20% of patients die on dialysis waiting for a deceased donor kidney.
Living kidney donation is a safe and proven treatment that leads to even better patient and health system outcomes than deceased donor kidney transplant. The Kidney Health Strategic Clinical Network (KH-SCN) identified increasing living kidney donation as a priority and in 2015 established the Living Donor Kidney Transplant Working Group (LDKTWG) comprised of patients, donors, health care professionals, researchers, and administrators. In an evidenced review published by the investigators, the intervention with the best evidence and greatest impact was personalized support provided by a multidisciplinary team to inform and educate the patients' social network. This intervention increased living kidney donations by 34%. The investigators confirmed through a province wide survey that many patients with kidney failure are unable to find a living kidney donor and find it difficult to approach potential donors due to lack of skills, supports, and resources and these issues are particularly apparent in vulnerable populations. The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support patients in identifying and communicating with their social networks. The investigators will test the effectiveness of this intervention.
Read the detailed description
Living donor kidney transplantation is the optimal treatment for end-stage kidney disease patients, dramatically improving survival and quality of life, providing significant cost saving compared with dialysis, reducing the demand for deceased donor transplants and the pressure to increase dialysis capacity and infrastructure. Outcome data shows that only 16% of Canadians on dialysis survive past 10 years, whereas up to 74% of Canadians with a kidney transplant have a functioning kidney after 10 years. The ideal treatment trajectory is to avoid dialysis entirely and receive a living donor transplant prior to dialysis (pre-emptive), which unfortunately only occurs in 10.5% of eligible patients.
Patients with end-stage kidney disease report being overwhelmed with other issues (loss of work, family stress, fear of dialysis) and lack the skills needed to comfortably engage potential living donors - many feel uncomfortable doing so and do not know how to start. The purpose of this research is to test an intervention designed to support patients identification of potential donors and communication with their social network and ultimately increase the number of living donor kidney transplantations.
Justification:
The rate of living kidney donor transplantation is lower in Alberta compared to other provinces in Canada. As the rate of kidney failure has increased over the past few years in Alberta, it is necessary to improve and facilitate the process of living kidney donor transplantation for better patient care.
Primary Objective:
The primary objective of this study is to examine the efficacy of the MuST AKT program to facilitate patients' identification of potential living kidney donors compared to usual care.
Hypothesis:
The investigators hypothesize that the MuST AKT program will increase the proportion of participants with at least one potential living kidney donors who started evaluation (intervention vs control).
Additional Objectives:
The secondary objective is to evaluate patient outcome improvement by collecting Patient Reported Outcome Measures (PROMs) to assess the proportion of patients who find at least one potential living donor.
The tertiary objective is to evaluate patient experience by collecting Patient Reported Experience Measures (PREMs) to determine whether participants recommend this program to other patients and to what extent this program gave them confidence for finding a potential living kidney donor.
The quaternary objective is to evaluate the feasibility of this program by assessing consent rate, attendance, adherence, and drop-out.
Research Methods/Procedures:
This is a pilot parallel randomized controlled trial with a qualitative interview component. The intervention condition will receive a multidisciplinary, tailored person-centered intervention over three months (MuST AKT program), and the control condition will receive the current standard of care (social worker assessment).
Patients who have been referred for kidney transplantation assessment in Edmonton will be contacted during a standard care kidney transplant education session or over the telephone if patients have completed the transplant education and are on the deceased kidney donor wait-list. Patients who expressed interest will be contacted via telephone by a member of the research team to seek their consent, complete the initial screening assessment to confirm their eligibility and enrolment, and then complete a baseline questionnaire. Then participants will be randomized to either the intervention or control condition, using predetermined randomly-generated (by Stata MP 15·1) permuted blocks of 4 and 6. Assignment to condition will be concealed by the database up until the point of assignment. Participants in the intervention condition will receive the MuST AKT program and participants in the control condition will receive usual care. Consent rate, attendance, adherence, and drop-out will be tracked during enrollment and the duration of the intervention. Upon completion of the intervention (or usual care), participants will complete a post-intervention questionnaire to assess PREMs. Participants in the intervention condition will be contacted after they have completed the post-questionnaire to participate in a qualitative interview lasting approximately 40 minutes. Kidney transplant status will be tracked for a period of 24 months post-intervention. Participants in the intervention condition who do not have a potential donor come forward after 12 months will be contacted to complete an additional interview to explore factors contributing to their lack of success, which will last approximately 40 minutes.
Intervention Condition: MuST AKT is a multidisciplinary, tailored person-centered intervention aimed to support participants identification of potential donors and communication with their social network. A one-on-one introductory session will be followed by three 'one-on-one' sessions (A, B and C) and a final session D with participants family and friends (potential donors and advocates) identified in session A. All group and individual sessions will be arranged virtually during the COVID-19 pandemic, and may be held either virtually or in-person, at the participants discretion, in the event that the COVID-19 pandemic concludes and physical distancing requirements have been eliminated. Each education session will take approximately 90 minutes. Sessions will be facilitated by a trained licensed social worker, coordinator or social media expert with extra training in kidney disease, transplantation, living kidney donation, counselling and interviewing, and patient confidentiality.
Usual care (control condition): In the control condition, participants will go through the current standard of care, which is a social worker assessment. If the intervention is successful in the definitive RCT (to be conducted later) and approved by Alberta Health Services as the 'new standard of care', people in control condition will be contacted and given the option to participate in the MuST AKT program.
Additional interviews with separate informed consent procedures:
(Patients) If, during recruitment for the study, the individual indicates they do not want to participate, or if participants drop-out of the study, a research team member will invite them participate in a 20-40 minute interview to understand barriers to participation in the study.
(Friends and family of patients) Friends and family members of participants who take part in session D will be invited to participate in an interview approximately 40 minutes long which aims to explore their experiences of group session D.
Plan for Data Analysis - Quantitative:
All analyses will be completed in Stata/MP 17.0 (www.stata.com), using an intention-to-treat approach. The investigators will use the Fisher's exact tests (dichotomous outcomes) and t-tests or Wilcoxon rank-sum tests (continuous outcomes data), as appropriate.
Our primary analyses (of our primary and secondary outcomes #1-4) will pool data from both the current and the definitive trials. In secondary analyses, the investigators will generate within trial results to investigate potential heterogeneity of intervention delivery.
Plan for Data Analysis - Qualitative Telephone interviews will be conducted using semi-structured interview guides. Data will be analyzed using a thematic analysis approach, whereby common themes that emerge from the data are documented. The qualitative software NVivo-12 will be used in the analysis.
- Conditions
- Living Donor Kidney Transplantation
- Being tested
- MuST AKT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MuST AKTBehavioural
A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to "help and enable" the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation. Receives: Behavioral: MuST AKT |
| Usual Care (control) | No intervention | In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Living Kidney Donor Evaluation Started
Proportion of participants with at least one potential donor who started evaluation
Measured: 12 months
Secondary outcomes (4)
Living Kidney Donor Transplantation
Proportion of living kidney donor transplantations
Measured: 24 months
Contact Living Donor Services
Proportion of participants with at least one potential donor who contacted living donor services
Measured: 12 months
Living Kidney Donor Evaluation Completed
Proportion of participants with at least one potential donor who completed evaluation
Measured: 12 months
Identified potential advocates
Number of participants who found at least one potential advocate
Measured: From date of first to last documented session, an average of 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2020
- Study start12 May 2021
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Living Donor Kidney TransplantationStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Pilot parallel block randomized controlled trial
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital Foundation
- Responsible party
- Sponsor
- Investigators
- Dr. Shojai, Principal investigator, University of Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04666545
- Sponsor's protocol ID
- Pro00097902
- Acronym
- MuST AKT
- Status last verified
- Jan 2026
- First submitted
- 23 Nov 2020
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, Vandermeer B, Corradetti B, Dhaliwal A, Ferdinand S, Ikekekpolor D, Smith G, Bello AK, Wen K, Shojai S. The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial. Transpl Int. 2026 Feb 25;39:15472. doi: 10.3389/ti.2026.15472. eCollection 2026.
PubMed 41822027Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, Wiebe N, Corradetti B, Ferdinand S, Iyekekpolor D, Smith G, Verdin N, Bello AK, Wen K, Shojai S; Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) Research Group. Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT): A Clinical Research Protocol for a Pilot Randomized Controlled Trial to Increase Living Kidney Donation. Can J Kidney Health Dis. 2023 Oct 30;10:20543581231205340. doi: 10.1177/20543581231205340. eCollection 2023.
PubMed 37920779
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multidisciplinary Support To Access Living Donor Kidney Transplant (MuST AKT)- A Pilot Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04666545
- Acronym / sponsor ID
- MuST AKT / Pro00097902
- Conditions
- Living Donor Kidney Transplantation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 38 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- University Hospital Foundation
- Study start
- 12 May 2021 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 14 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For patients with kidney failure the two treatment options are kidney transplantation or dialysis. Transplantation offers longer survival, better quality of life and provides cost savings for the health system (>$60,000/year per patient). Unfortunately, there are not enough organs available and 20% of patients die on dialysis waiting for a deceased donor kidney.
Living kidney donation is a safe and proven treatment that leads to even better patient and health system outcomes than deceased donor kidney transplant. The Kidney Health Strategic Clinical Network (KH-SCN) identified increasing living kidney donation as a priority and in 2015 established the Living Donor Kidney Transplant Working Group (LDKTWG) comprised of patients, donors, health care professionals, researchers, and administrators. In an evidenced review published by the investigators, the intervention with the best evidence and greatest impact was personalized support provided by a multidisciplinary team to inform and educate the patients' social network. This intervention increased living kidney donations by 34%. The investigators confirmed through a province wide survey that many patients with kidney failure are unable to find a living kidney donor and find it difficult to approach potential donors due to lack of skills, supports, and resources and these issues are particularly apparent in vulnerable populations. The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support patients in identifying and communicating with their social networks. The investigators will test the effectiveness of this intervention.
Detailed description
Living donor kidney transplantation is the optimal treatment for end-stage kidney disease patients, dramatically improving survival and quality of life, providing significant cost saving compared with dialysis, reducing the demand for deceased donor transplants and the pressure to increase dialysis capacity and infrastructure. Outcome data shows that only 16% of Canadians on dialysis survive past 10 years, whereas up to 74% of Canadians with a kidney transplant have a functioning kidney after 10 years. The ideal treatment trajectory is to avoid dialysis entirely and receive a living donor transplant prior to dialysis (pre-emptive), which unfortunately only occurs in 10.5% of eligible patients.
Patients with end-stage kidney disease report being overwhelmed with other issues (loss of work, family stress, fear of dialysis) and lack the skills needed to comfortably engage potential living donors - many feel uncomfortable doing so and do not know how to start. The purpose of this research is to test an intervention designed to support patients identification of potential donors and communication with their social network and ultimately increase the number of living donor kidney transplantations.
Justification:
The rate of living kidney donor transplantation is lower in Alberta compared to other provinces in Canada. As the rate of kidney failure has increased over the past few years in Alberta, it is necessary to improve and facilitate the process of living kidney donor transplantation for better patient care.
Primary Objective:
The primary objective of this study is to examine the efficacy of the MuST AKT program to facilitate patients' identification of potential living kidney donors compared to usual care.
Hypothesis:
The investigators hypothesize that the MuST AKT program will increase the proportion of participants with at least one potential living kidney donors who started evaluation (intervention vs control).
Additional Objectives:
The secondary objective is to evaluate patient outcome improvement by collecting Patient Reported Outcome Measures (PROMs) to assess the proportion of patients who find at least one potential living donor.
The tertiary objective is to evaluate patient experience by collecting Patient Reported Experience Measures (PREMs) to determine whether participants recommend this program to other patients and to what extent this program gave them confidence for finding a potential living kidney donor.
The quaternary objective is to evaluate the feasibility of this program by assessing consent rate, attendance, adherence, and drop-out.
Research Methods/Procedures:
This is a pilot parallel randomized controlled trial with a qualitative interview component. The intervention condition will receive a multidisciplinary, tailored person-centered intervention over three months (MuST AKT program), and the control condition will receive the current standard of care (social worker assessment).
Patients who have been referred for kidney transplantation assessment in Edmonton will be contacted during a standard care kidney transplant education session or over the telephone if patients have completed the transplant education and are on the deceased kidney donor wait-list. Patients who expressed interest will be contacted via telephone by a member of the research team to seek their consent, complete the initial screening assessment to confirm their eligibility and enrolment, and then complete a baseline questionnaire. Then participants will be randomized to either the intervention or control condition, using predetermined randomly-generated (by Stata MP 15·1) permuted blocks of 4 and 6. Assignment to condition will be concealed by the database up until the point of assignment. Participants in the intervention condition will receive the MuST AKT program and participants in the control condition will receive usual care. Consent rate, attendance, adherence, and drop-out will be tracked during enrollment and the duration of the intervention. Upon completion of the intervention (or usual care), participants will complete a post-intervention questionnaire to assess PREMs. Participants in the intervention condition will be contacted after they have completed the post-questionnaire to participate in a qualitative interview lasting approximately 40 minutes. Kidney transplant status will be tracked for a period of 24 months post-intervention. Participants in the intervention condition who do not have a potential donor come forward after 12 months will be contacted to complete an additional interview to explore factors contributing to their lack of success, which will last approximately 40 minutes.
Intervention Condition: MuST AKT is a multidisciplinary, tailored person-centered intervention aimed to support participants identification of potential donors and communication with their social network. A one-on-one introductory session will be followed by three 'one-on-one' sessions (A, B and C) and a final session D with participants family and friends (potential donors and advocates) identified in session A. All group and individual sessions will be arranged virtually during the COVID-19 pandemic, and may be held either virtually or in-person, at the participants discretion, in the event that the COVID-19 pandemic concludes and physical distancing requirements have been eliminated. Each education session will take approximately 90 minutes. Sessions will be facilitated by a trained licensed social worker, coordinator or social media expert with extra training in kidney disease, transplantation, living kidney donation, counselling and interviewing, and patient confidentiality.
Usual care (control condition): In the control condition, participants will go through the current standard of care, which is a social worker assessment. If the intervention is successful in the definitive RCT (to be conducted later) and approved by Alberta Health Services as the 'new standard of care', people in control condition will be contacted and given the option to participate in the MuST AKT program.
Additional interviews with separate informed consent procedures:
(Patients) If, during recruitment for the study, the individual indicates they do not want to participate, or if participants drop-out of the study, a research team member will invite them participate in a 20-40 minute interview to understand barriers to participation in the study.
(Friends and family of patients) Friends and family members of participants who take part in session D will be invited to participate in an interview approximately 40 minutes long which aims to explore their experiences of group session D.
Plan for Data Analysis - Quantitative:
All analyses will be completed in Stata/MP 17.0 (www.stata.com), using an intention-to-treat approach. The investigators will use the Fisher's exact tests (dichotomous outcomes) and t-tests or Wilcoxon rank-sum tests (continuous outcomes data), as appropriate.
Our primary analyses (of our primary and secondary outcomes #1-4) will pool data from both the current and the definitive trials. In secondary analyses, the investigators will generate within trial results to investigate potential heterogeneity of intervention delivery.
Plan for Data Analysis - Qualitative Telephone interviews will be conducted using semi-structured interview guides. Data will be analyzed using a thematic analysis approach, whereby common themes that emerge from the data are documented. The qualitative software NVivo-12 will be used in the analysis.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- Pilot parallel block randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: MuST AKTThis arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to "help and enable" the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation. |
| Usual Care (control) | No intervention | –In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- English speaking
- No obvious contraindication to kidney transplantation
- Completed 'introduction to kidney transplant' module
Key exclusion criteria (5 listed)
- Potential Living Kidney Donor identified
- Previously received organ transplant
- Candidate for multi-organ transplant
- Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) Score > 20
- Rapid Estimate of Adult Literacy in Medicine (REALM-66) score < 19 (illiterate in English)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MuST AKTA behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation. | Behavioural | Intervention |
Primary outcome
Living Kidney Donor Evaluation Started
Time frame: 12 months
Proportion of participants with at least one potential donor who started evaluation
4 secondary outcomes
Living Kidney Donor Transplantation
Time frame: 24 months
Contact Living Donor Services
Time frame: 12 months
Living Kidney Donor Evaluation Completed
Time frame: 12 months
Identified potential advocates
Time frame: From date of first to last documented session, an average of 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Derived from this study: PubMed 41822027Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, Vandermeer B, Corradetti B, Dhaliwal A, Ferdinand S, Ikekekpolor D, Smith G, Bello AK, Wen K, Shojai S. The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial. Transpl Int. 2026 Feb 25;39:15472. doi: 10.3389/ti.2026.15472. eCollection 2026.
- Derived from this study: PubMed 37920779Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, Wiebe N, Corradetti B, Ferdinand S, Iyekekpolor D, Smith G, Verdin N, Bello AK, Wen K, Shojai S; Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) Research Group. Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT): A Clinical Research Protocol for a Pilot Randomized Controlled Trial to Increase Living Kidney Donation. Can J Kidney Health Dis. 2023 Oct 30;10:20543581231205340. doi: 10.1177/20543581231205340. eCollection 2023.
- Individual participant dataSharing planned: No
Related trials for Living Donor Kidney Transplantation
Not yet recruitingPhase 1
ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications
Not yet recruiting
Prophylactic Norepinephrine for Prevention of Acute Kidney Injury in Living-Donor Liver Transplantation
Noradrenaline
Not yet recruiting
Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation
End-Stage Renal Disease, Chronic Kidney Diseases
Enrolling by invitationPhase 4
Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients
Postoperative Pain
Active, not recruitingPhase 1/2
Cell Therapy for Immunomodulation in Kidney Transplantation
Kidney Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Shojai principal investigator
University of Alberta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MuST AKT in people with Living Donor Kidney Transplantation, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Living Kidney Donor Evaluation Started (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04666545, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.